Complications of HIV disease and antiretroviral therapy

Topics in Antiviral Medicine

Volumn 20, Issue 2, 2012, Pages 48-60

  Luetkemeyer, Anne F ^a   Havlir, Diane V ^a,b   Currier, Judith S ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; RIBAVIRIN;

DRUG INTERACTION; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; REVIEW;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERONS; RIBAVIRIN;

EID: 84867852582     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-2416.
2. Rivero-Juarez A, Mira JA, Perez-Camacho I, et al. Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus coinfected patients. J Antimicrob Chemother. 2011;66:1351-1353.
3. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433-1444.
4. US Food and Drug Administration. Victrelis (boceprevir) and ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitor drugs: drug safety communication-drug interactions. http:// www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedical-Products/ucm291144.htm. Accessed April 27, 2012.
5. Van Heeswijk R, Garg V, Vandevoorde A, Witek J, Dannemann B. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers [Abstract 1738a]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 17-20, 2011; Chicago, IL.
6. Gane EJ, Stedman CA, Hyland RH, et al. Once daily PSI-7977 plus RBV: pegylated interferon-alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3 [Abstract 34]. 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD). November 4-8, 2011; San Francisco, CA.
7. Gane EJ, Stedman CA, Hyland RH, et al. ELECTRON: Once Daily PSI-7977 plus RBV in HCV GT1/2/3 [Abstract 1113]. 47th Annual Meeting of the European Association for the Study of the Liver. April 18-12, 2012; Barcelona, Spain.
8. The Fundación Investigació y Educación en SIDA (FIES). Prometheus index. http:// www.fundacionies.com/prometheusindex. php?lang=ing. Accessed May 2, 2012.
9. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999;30:1302-1306.
10. Zackin RA, Clark RA, Currier JS, Mildvan D. Predictive markers of HIV-related weight loss and determination of differences between populations with weight loss stratified by opportunistic processes. JAIDS. 1999;22:189-193.
11. Freitas P, Santos AC, Carvalho D, et al. Fat mass ratio: an objective tool to define lipodystrophy in HIV-infected patients under antiretroviral therapy. J Clin Densitom. 2010;13:197-203.
12. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with lowdose computed tomographic screening. N Engl J Med. 2011;365:395-409.
13. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol. 2004;22:2388-2394.
14. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352:2184-2192.
15. Karp I, Behlouli H, Lelorier J, Pilote L. Statins and cancer risk. Am J Med. 2008;121:302-309.
16. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
17. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA. 2006;295:74-80.